Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
Duodecim; Laaketieteellinen Aikakauskirja|March 15, 2013
[Woman, hormones and migraine]Marja-Liisa SumelahtiActa Neurologica Scandinavica|December 16, 2019
Multiple sclerosis prevalence in 2000 and 2010 in Western FinlandAnnukka Murtonen, Marja-Liisa SumelahtiNeuroepidemiology|August 19, 2004
Cancer incidence in multiple sclerosis: a 35-year follow-upMarja-Liisa Sumelahti, Eero Pukkala, Matti HakamaNeurology International|October 21, 2016
Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical EffectivenessElina Järvinen, Markus Holmberg, Marja-Liisa SumelahtiClinical Therapeutics|February 18, 2017
Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple SclerosisErkki Soini, Jaana Joutseno, Marja-Liisa SumelahtiBMC Medical Education|April 6, 2017
Medical students' experience of emotions and success in neurological studies - What do they tell us?Hanna Ansakorpi, Marja-Liisa Sumelahti, Raimo KaasilaMultiple Sclerosis and Related Disorders|July 17, 2021
End of life in multiple sclerosis: Disability, causes and place of death among cases diagnosed from 1981 to 2010 in Pirkanmaa hospital district in Western FinlandAnnukka Murtonen, Juho T Lehto, Marja-Liisa SumelahtiMultiple Sclerosis (Houndmills, Basingstoke, England)|September 10, 2010
Causes of death among patients with multiple sclerosisMarja-Liisa Sumelahti, Matti Hakama, Irina Elovaara, et al.Neurology International|December 25, 2019
Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in FinlandElina Järvinen, Annukka Murtonen, Melina Tervomaa, et al.Journal of the Neurological Sciences|September 9, 2022
Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up studyJulia Vistbakka, Marja-Liisa Sumelahti, Terho Lehtimäki, et al.Pageof 5